#Cancer_Trials

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

First Patient Enrolled for IDEAYA's Innovative Cancer Treatment Trial with IDE034 IDEAYA Biosciences has announced the enrollment of its first patient in the Phase 1 trial of IDE034, targeting specific types of cancers with promising results.

First Patient Enrolled for IDEAYA's Innovative Cancer Treatment Trial with IDE034 #United_States #IDEAYA_Biosciences #South_San_Francisco #Cancer_Trials #IDE034

Thiard News@F4F

@newsen.bsky.social

3 months ago

Northwell Health Launches State-of-the-Art Cancer Trial Center in Long Island Northwell Health and START Center for Cancer Research unveil an advanced clinical trial center in Long Island, expanding access to cutting-edge cancer treatments.

Northwell Health Launches State-of-the-Art Cancer Trial Center in Long Island #United_States #Cancer_Trials #START_Center #Northwell_Health #Lake_Success

Thiard News@F4F

@newsen.bsky.social

7 months ago

HopeAI Revolutionizes Cancer Drug Trials Using AI-Generated Synthetic Data at ASCO 2025 HopeAI showcases its innovative application of AI-generated synthetic data to enhance the efficiency of cancer drug trials at ASCO 2025.

HopeAI Revolutionizes Cancer Drug Trials Using AI-Generated Synthetic Data at ASCO 2025 #United_States #New_York #Cancer_Trials #ASCO_2025 #HopeAI

Thiard News@F4F

@newsen.bsky.social

8 months ago

START Launches Hope Hub for Enhanced Access to Cancer Trial Information The START Center introduces the Hope Hub, a revolutionary platform aimed at improving access to cancer clinical trials for patients, physicians, and advocacy groups. This initiative promises to connect communities effectively.

START Launches Hope Hub for Enhanced Access to Cancer Trial Information #United_States #San_Antonio #Cancer_Trials #START_Center #Hope_Hub

Thiard News@F4F

@newsen.bsky.social

9 months ago

Novita Pharmaceuticals Presents Exciting Phase 2 Trial Data for NP-G2-044 in Metastatic Solid Tumors at ASCO 2025 At the 2025 ASCO Annual Meeting, Novita Pharmaceuticals revealed encouraging findings from its Phase 2 NP-G2-044 trial for advanced solid tumors.

Novita Pharmaceuticals Presents Exciting Phase 2 Trial Data for NP-G2-044 in Metastatic Solid Tumors at ASCO 2025 #USA #New_York #Cancer_Trials #NP-G2-044 #Novita

Thiard News@F4F

@newsen.bsky.social

9 months ago

Leukemia & Lymphoma Society Opens Grant Applications for Enhanced Cancer Trial Access The Leukemia & Lymphoma Society has launched a new grant application process aimed at improving access to cancer clinical trials for underrepresented groups. Up to $2.5 million is available per study.

Leukemia & Lymphoma Society Opens Grant Applications for Enhanced Cancer Trial Access #USA #Cancer_Trials #Leukemia_Society #Equity_Research #RYE_BROOK,_NY

Thiard News@F4F

@newsen.bsky.social

9 months ago

Trial Library Collaboration with Texas Oncology Revolutionizes Access to Clinical Trials for Cancer Patients Trial Library partners with Texas Oncology to improve access to clinical trials, leveraging technology to guide patients through vital cancer research.

Trial Library Collaboration with Texas Oncology Revolutionizes Access to Clinical Trials for Cancer Patients #United_States #San_Francisco #Cancer_Trials #Trial_Library #Texas_Oncology

Thiard News@F4F

@newsen.bsky.social

9 months ago

AI Innovations Revolutionizing Healthcare: From Diagnostics to Treatment Artificial intelligence is rapidly transforming healthcare, enhancing diagnostics and personalized care. Learn how companies like Avant Technologies are leading this change.

AI Innovations Revolutionizing Healthcare: From Diagnostics to Treatment #Canada #Vancouver #AI_in_Healthcare #Avant_Technologies #Cancer_Trials

Thiard News@F4F

@newsen.bsky.social

10 months ago

Intensity Therapeutics Initiates $2.35 Million Public Offering for Cancer Treatment Advancements Intensity Therapeutics has announced a $2.35 million public offering aimed at furthering its innovative cancer therapies. This funding will support ongoing clinical trials and patient enrollments.

Intensity Therapeutics Initiates $2.35 Million Public Offering for Cancer Treatment Advancements #United_States #Public_Offering #Intensity_Therapeutics #Shelton #Cancer_Trials

Thiard News@F4F

@newsen.bsky.social

1 year ago

Taiho Oncology's Decitabine and Cedazuridine to Feature in NIH Precision Medicine Trials for Cancer Taiho Oncology announces that its oral treatments, decitabine and cedazuridine, will be used in NIH trials for myelodysplastic syndromes and AML.

Taiho Oncology's Decitabine and Cedazuridine to Feature in NIH Precision Medicine Trials for Cancer #United_States #Princeton #Precision_Medicine #Taiho_Oncology #Cancer_Trials